Drug developer Veru Inc on Tuesday stated it plans to proceed with a late-stage trial of its COVID-19 tablet, weeks after the U.S. well being regulator declined to authorize the oral drug to deal with high-risk sufferers hospitalized with COVID-19.
It would, nonetheless, cease the event of the drug as a possible remedy for prostate most cancers as a part of its technique to chop prices.
Veru plans to proceed improvement of the oral drug, sabizabulin, in late-stage research with high-risk hospitalized influenza sufferers and COVID-19 sufferers. It expects to report interim information from the COVID-19 trial subsequent yr.
TILDA SWINTON IS DONE WITH COVID MANDATES: ‘I’M NOT WEARING A MASK’
CLICK HERE TO GET THE FOX NEWS APP
The corporate stated it was planning to satisfy the U.S. Meals and Drug Administration quickly and can talk particulars of the late-stage trial after the assembly.
Moreover, Veru will cease the event of two of its different most cancers drug candidates – VERU-100 and zuclomiphene – which it was testing in mid-stage research for varied indications.
Shares of the corporate rose almost 3% to $2.09 in afternoon commerce.